Fundamental Data for NTMD

Nitromed Inc is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. The Company utilizes its nitric oxide expertise and technology in an effort both to develop novel pharmaceuticals and to improve the safety and efficacy of widely-prescribed drugs.

# Employees: 88

Address: 45 Hayden Avenue Suite 3000,Lexington,MA,USA

Phone: 781 266-4000

Fax: 781 274-8080

Website: www.nitromed.com

Email: investors@nitromed.com

Sector: Medical

Industry: MED-DRUGS

Executive Officers

Kenneth M. Bate (Presi.; C.E.O.; Dir.)

James G. Ham III (V.P.; C.F.O.; Tres. & Sec.)

Robert S. Cohen (Dir.)

Frank L. Douglas MD (Ph)

Dir. (Zola Horovitz Ph.D.,Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 12/31/2008

Next Earnings Date(Expected): 5/6/2009

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	NTMD	Compare to S&P
YTD	-0.01 %	133.58 %
4 Weeks	-0.01 %	-0.01 %
12 Weeks	-0.01 %	-0.01 %

Shares Information

Analyst Coverage: N

Avg Volume: 146218

Shares Outstanding: 46M

Market Cap: ($0.01)M

52 Week High: $1.28

52 Week Low: ($0.01)

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 NTMD split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -200.00 %

EPS Growth in Last Year: 80.00 %

Sales Growth in Last Quarter: -21.23 %

Sales Growth in Last Quarter: -36.65 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010